Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

598 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of intraperitoneal chemotherapy for the treatment of gastric cancer with peritoneal metastasis: A comprehensive systematic review and meta-analysis.
Boshier PR, Tekkis N, Baggaley A, Robb HD, Lafaurie G, Simkens G, Nilsson M, Hanna GB, Petty R. Boshier PR, et al. Among authors: petty r. Eur J Surg Oncol. 2024 Nov 24;51(2):109499. doi: 10.1016/j.ejso.2024.109499. Online ahead of print. Eur J Surg Oncol. 2024. PMID: 39644811 Free article. Review.
REsolution of Symptoms afTer Oesophago-gastric cancer REsection delphi (RESTOREd)-standardizing the definition, investigation and management of gastrointestinal symptoms and conditions after surgery.
Byrne BE, Siaw-Acheampong K, Evans O, Taylor J, Huddy F, Nilsson M, Griffiths EA, Low D, Gossage J, Dunn J, Zeki S, Markar S, Avery K, Blazeby JM, Cockbain A, Moss C, van Hemelrijck M, Andreyev J, Davies AR; RESTORE Delphi study group. Byrne BE, et al. Br J Surg. 2024 Nov 27;111(12):znae286. doi: 10.1093/bjs/znae286. Br J Surg. 2024. PMID: 39657739
Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study.
Fong C, Patel B, Peckitt C, Bourmpaki E, Satchwell L, Cromarty S, Kidd S, von Loga K, Uhlik M, Begum R, Rana T, Waddell T, Darby S, Bradshaw A, Roques T, Morgan C, Rees C, Herbertson R, Das P, Thompson C, Hewish M, Petty R, Thistlethwaite F, Rao S, Starling N, Chau I, Cunningham D. Fong C, et al. Among authors: petty r. ESMO Open. 2024 Jul;9(7):103622. doi: 10.1016/j.esmoop.2024.103622. Epub 2024 Jul 13. ESMO Open. 2024. PMID: 39002179 Free PMC article. Clinical Trial.
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group. Fuchs CS, et al. Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1. Lancet Oncol. 2019. PMID: 30718072 Clinical Trial.
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Joharatnam-Hogan N, Cafferty F, Hubner R, Swinson D, Sothi S, Gupta K, Falk S, Patel K, Warner N, Kunene V, Rowley S, Khabra K, Underwood T, Jankowski J, Bridgewater J, Crossley A, Henson V, Berkman L, Gilbert D, Kynaston H, Ring A, Cameron D, Din F, Graham J, Iveson T, Adams R, Thomas A, Wilson R, Pramesh CS, Langley R; Add-Aspirin Trial Management Group. Joharatnam-Hogan N, et al. Lancet Gastroenterol Hepatol. 2019 Nov;4(11):854-862. doi: 10.1016/S2468-1253(19)30289-4. Epub 2019 Aug 30. Lancet Gastroenterol Hepatol. 2019. PMID: 31477558 Free article. Clinical Trial.
Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.
Ganguli P, Basanta CC, Acha-Sagredo A, Misetic H, Armero M, Mendez A, Zahra A, Devonshire G, Kelly G, Freeman A, Green M, Nye E, Bichisecchi A, Bonfanti P; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium; Rodriguez-Justo M, Spencer J, Fitzgerald RC, Ciccarelli FD. Ganguli P, et al. Nat Cancer. 2025 Jan 3. doi: 10.1038/s43018-024-00876-0. Online ahead of print. Nat Cancer. 2025. PMID: 39753721
Generation of a selective senolytic platform using a micelle-encapsulated Sudan Black B conjugated analog.
Magkouta S, Veroutis D, Papaspyropoulos A, Georgiou M, Lougiakis N, Pippa N, Havaki S, Palaiologou A, Thanos DF, Kambas K, Lagopati N, Boukos N, Pouli N, Marakos P, Kotsinas A, Thanos D, Evangelou K, Sampaziotis F, Tamvakopoulos C, Pispas S, Petty R, Kotopoulos N, Gorgoulis VG. Magkouta S, et al. Among authors: petty r. Nat Aging. 2024 Dec 27. doi: 10.1038/s43587-024-00747-4. Online ahead of print. Nat Aging. 2024. PMID: 39730824
Decoding T cell senescence in cancer: Is revisiting required?
Magkouta S, Markaki E, Evangelou K, Petty R, Verginis P, Gorgoulis V. Magkouta S, et al. Among authors: petty r. Semin Cancer Biol. 2024 Nov 29;108:33-47. doi: 10.1016/j.semcancer.2024.11.003. Online ahead of print. Semin Cancer Biol. 2024. PMID: 39615809 Review.
iDiabetes platform-enhanced phenotyping of patients with diabetes for precision diagnosis, prognosis and treatment: study protocol for a cluster-randomised controlled study in Tayside, Scotland.
Lin Y, Leith D, Abbott M, Barrett R, Bell S, Croudace TJ, Cunningham S, Dillon J, Donnan P, Farre A, Hernández R, Lang C, McKenzie S, Mordi I, Morrow S, Munro C, Philip S, Ryan M, Wake D, Wang H, Win M, Pearson E; iDiabetes Study Team; iDiabetes Study Team. Lin Y, et al. BMJ Open. 2024 Nov 28;14(11):e086594. doi: 10.1136/bmjopen-2024-086594. BMJ Open. 2024. PMID: 39613429 Free PMC article.
598 results